BRPI0511261A - linhagem isolada de lactobacillus sp., uso de uma linhagem isolada de lactobacillus sp., e composição farmacêutica - Google Patents
linhagem isolada de lactobacillus sp., uso de uma linhagem isolada de lactobacillus sp., e composição farmacêuticaInfo
- Publication number
- BRPI0511261A BRPI0511261A BRPI0511261-3A BRPI0511261A BRPI0511261A BR PI0511261 A BRPI0511261 A BR PI0511261A BR PI0511261 A BRPI0511261 A BR PI0511261A BR PI0511261 A BRPI0511261 A BR PI0511261A
- Authority
- BR
- Brazil
- Prior art keywords
- lactobacillus
- strain
- thymidine
- isolated lactobacillus
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
- C12N9/1007—Methyltransferases (general) (2.1.1.)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K2035/11—Medicinal preparations comprising living procariotic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
LINHAGEM ISOLADA DE LACTOBACILLUS SP., USO DE UMA LINHAGEM ISOLADA DE LACTOBACILLUS SP., E COMPOSIçãO FARMACêUTICA. A invenção está relacionada a uma linhagem Lactobacillus recombinante, com limitado crescimento e viabilidade no ambiente. Mais particularmente, ela está relacionada a um Lactobacillus recombinante que pode apenas sobreviver em um meio, onde timidina está presente. Por meio dessa estrita dependência da ação da timidina, a morte por falta da timidina é rapidamente induzida nessa linhagem recombinante. Uma modalidade preferida é um Lactobacillus que pode apenas sobreviver em um organismo hospedeiro, onde timidina está presente, mas não pode sobreviver fora do organismo hospedeiro em ausência desse composto meio. Além disso, a referida linhagem Lactobacillus pode ser transformada com moléculas profiláticas e/ou terapêuticas e pode, como tal, ser usada para tratar doenças tais como, mas não limitado a, doenças inflamatórias dos intestinos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04102202 | 2004-05-18 | ||
| PCT/EP2005/052296 WO2005111194A1 (en) | 2004-05-18 | 2005-05-18 | Self-containing lactobacillus strain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0511261A true BRPI0511261A (pt) | 2007-11-27 |
Family
ID=34929115
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0511261-3A BRPI0511261A (pt) | 2004-05-18 | 2005-05-18 | linhagem isolada de lactobacillus sp., uso de uma linhagem isolada de lactobacillus sp., e composição farmacêutica |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20080253990A1 (pt) |
| EP (1) | EP1751270A1 (pt) |
| JP (1) | JP2007537741A (pt) |
| KR (1) | KR20070026575A (pt) |
| CN (1) | CN101052705A (pt) |
| AU (1) | AU2005243441A1 (pt) |
| BR (1) | BRPI0511261A (pt) |
| CA (1) | CA2567106A1 (pt) |
| WO (1) | WO2005111194A1 (pt) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8682619B2 (en) | 2005-12-14 | 2014-03-25 | The Invention Science Fund I, Llc | Device including altered microorganisms, and methods and systems of use |
| US8278094B2 (en) | 2005-12-14 | 2012-10-02 | The Invention Science Fund I, Llc | Bone semi-permeable device |
| US8734823B2 (en) | 2005-12-14 | 2014-05-27 | The Invention Science Fund I, Llc | Device including altered microorganisms, and methods and systems of use |
| US8852916B2 (en) | 2010-01-22 | 2014-10-07 | The Invention Science Fund I, Llc | Compositions and methods for therapeutic delivery with microorganisms |
| EP2016178B1 (en) * | 2006-05-02 | 2017-07-12 | Intrexon Actobiotics NV | Microbial intestinal delivery of obesity related peptides |
| EP3181682B1 (en) | 2008-09-29 | 2021-04-21 | Intrexon Actobiotics NV | Reduced colonization of microbes at the mucosa |
| BR112012016982B8 (pt) | 2010-01-14 | 2022-12-20 | Institut National De Rech Pour Lagriculture Lalimentation Et Lenvironnement | bactéria de ácido lático recombinante de grau alimentício e composição terapêutica |
| HUE038336T2 (hu) | 2011-09-23 | 2018-10-29 | Intrexon Actobiotics Nv | Módosított gram-pozitív baktériumok és alkalmazásaik |
| JP6117212B2 (ja) | 2011-09-23 | 2017-04-19 | イントレクソン・アクトバイオテイクス・エヌブイIntrexon Actobiotics NV | 改変されたグラム陽性菌及びその使用 |
| WO2016124239A1 (en) * | 2015-02-04 | 2016-08-11 | Aurealis Oy | Recombinant probiotic bacteria for use in the treatment of a skin dysfunction |
| JP2022512639A (ja) * | 2018-10-09 | 2022-02-07 | セカンド ゲノム インコーポレイテッド | 上皮バリア機能障害の治療に有効なタンパク質を送達するためのラクトコッカス・ラクティス発現系 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003298291A1 (en) * | 2002-11-15 | 2004-06-15 | Universiteit Gent | Self-containing lactobacillus strain |
-
2005
- 2005-05-18 JP JP2007517259A patent/JP2007537741A/ja not_active Ceased
- 2005-05-18 EP EP05747682A patent/EP1751270A1/en not_active Withdrawn
- 2005-05-18 BR BRPI0511261-3A patent/BRPI0511261A/pt not_active Application Discontinuation
- 2005-05-18 CN CNA2005800160283A patent/CN101052705A/zh active Pending
- 2005-05-18 CA CA002567106A patent/CA2567106A1/en not_active Abandoned
- 2005-05-18 WO PCT/EP2005/052296 patent/WO2005111194A1/en not_active Ceased
- 2005-05-18 AU AU2005243441A patent/AU2005243441A1/en not_active Abandoned
- 2005-05-18 KR KR1020067026056A patent/KR20070026575A/ko not_active Withdrawn
- 2005-05-18 US US11/596,715 patent/US20080253990A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1751270A1 (en) | 2007-02-14 |
| US20080253990A1 (en) | 2008-10-16 |
| CA2567106A1 (en) | 2005-11-24 |
| JP2007537741A (ja) | 2007-12-27 |
| CN101052705A (zh) | 2007-10-10 |
| AU2005243441A1 (en) | 2005-11-24 |
| WO2005111194A1 (en) | 2005-11-24 |
| KR20070026575A (ko) | 2007-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0511261A (pt) | linhagem isolada de lactobacillus sp., uso de uma linhagem isolada de lactobacillus sp., e composição farmacêutica | |
| MX2020008772A (es) | Conjugados de il-15, y sus usos. | |
| NO20084749L (no) | Organiske forbindelser og deres anvendelser | |
| BR112021019880A2 (pt) | Terapias gênicas para distúrbios lisossomais | |
| ECSP10010735A (es) | Compuestos químicos 251 | |
| BR112012006144A2 (pt) | novas individualidades de heparina e métodos de uso. | |
| EP2494059A4 (en) | USE OF METHYLSULFONYLMETHANE (MSM) TO MODULATE MICROBIAL ACTIVITY | |
| UY31067A1 (es) | Inhibidores de proteina activadora de la 5-lipoxigenasa (flap) | |
| BRPI0510999A (pt) | dispositivo de eletrodesionização e métodos de uso | |
| BRPI1012219C1 (pt) | produto, substrato, composição farmacêutica, usos de um produto, e de um peptídeo antimicrobiano, métodos para prevenir formação de biofilme em um ambiente, para tratar uma infecção microbiana por profilaxia ou terapia, e para tratar ou prevenir formação de biofilme em um ambiente, e, uso de uma cisteamina | |
| BR112012027765A2 (pt) | métodos, composições e kits para tratamento de distúrbios de mineralização da matriz. | |
| BRPI0611717A2 (pt) | composto, composiÇço farmacÊutica e uso do composto | |
| MX2009009207A (es) | Metodos y composiciones para normalizar las secreciones de glandulas meibomianas. | |
| CR9480A (es) | Moduladores de la lta4h de fenilo y piridilo | |
| UY30918A1 (es) | Moduladores de lta4h y sus usos | |
| WO2007146730A3 (en) | Deacetylase inhibitor therapy | |
| GB2453475A (en) | Live vaccine strains of francisella | |
| MX2018014419A (es) | Composicion y metodos para la terapia de microbiota. | |
| CO2022000270A2 (es) | Inhibidores de enzimas | |
| WO2018175749A3 (en) | LRP1 BINDING AGENTS AND USES THEREOF | |
| ZA202006077B (en) | Human kynureninase enzymes and uses thereof | |
| BRPI0703029A (pt) | sistema cirúrgico a laser com funcionalidade de controle remoto | |
| MX392976B (es) | Composiciones que comprenden cepas bacterianas. | |
| BR112017002166A2 (pt) | terapias antibióticas de peptídeos derivados do búfalo d?água | |
| CO2021007006A2 (es) | Moduladores de la expresión de irf5 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired |